Blog Exposure - INSYS Commences Phase-2 Clinical Trial of Cannabidiol Oral Solution for Treatment of Prader-Willi Syndrome

Stock Monitor: Innoviva Post Earnings Reporting

LONDON, UK / ACCESSWIRE / May 01, 2018 / Active-Investors.com has just released a free research report on INSYS Therapeutics, Inc. (NASDAQ: INSY) ("INSYS"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=INSY as the Company's latest news hit the wire. On April 27, 2018, the Company announced that it has initiated a Phase-2 clinical trial assessing its cannabidiol (CBD) oral solution for the potential treatment of pediatric patients with Prader-Willi syndrome, which is a rare genetic disease characterized by insatiable appetite in children that often leads to obesity, type 2 diabetes, and premature death. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Innoviva, Inc. (NASDAQ: INVA), which also belongs to the Healthcare sector as the Company INSYS Therapeutics. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=INVA

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, INSYS Therapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=INSY

Phase-2 Trial Results Expected in Q4 2019

INSYS' Phase-2 study will measure the effect of its propriety CBD oral solution on the behavior related to hyperphagia, which is defined as an abnormally increased appetite for and consumption of food, in patients with Prader-Willi syndrome. The trial will enroll approximately 66 subjects, aged between 8 to 17 years, at 10 clinical sites in the United States, with results expected in Q4 2019.

CBD has the Potential to be an Important Addition to Limited Range of Treatment Options for Prader-Willi Syndrome

Steve Sherman, Senior Vice President of Regulatory Affairs for INSYS, mentioned that while Prader-Willi syndrome presents a complex constellation of symptoms to address, the Company's study will focus on one of the most challenging symptoms, hyperphagia. Sherman added that INSYS' formulation of CBD has the potential to be an important addition to the limited range of treatment options for this condition.

FDA Granted Fast Track Designation for Cannabidiol as Investigational Treatment for Prader-Willi Syndrome

On December 26, 2018, the US Food and Drug Administration (FDA) granted a Fast Track designation to cannabidiol (CBD) oral solution for the treatment of Prader-Willi syndrome. The FDA's Fast Track designation will enable an expedited regulatory review process for proprietary formulation of CBD in the treatment of pediatric patients with Prader-Willi syndrome.

INSYS Initiated Phase-3 Clinical Trial of Cannabidiol for Treatment of Infantile Spasms

On March 02, 2018, the Company began a Phase-3 clinical trial to study cannabidiol (CBD) oral solution for the treatment of infantile spasms, a rare type of pediatric epilepsy that occurs in very young children, with the first trial site's activation. In previous studies, CBD, one of the main molecules in cannabis, has demonstrated sustained clinical benefits in a variety of medically refractory pediatric epilepsies, including infantile spasms.

About Prader-Willi Syndrome

Prader-Willi syndrome is a genetic disorder due to the loss of function of specific genes. It is known as a two-stage syndrome, with the first stage characterized by hypotonia (low muscle tone) and poor feeding in infancy, and the second stage exhibiting hyperphagia (an uncontrollable drive to eat), combined with weight gain on fewer calories. Beginning in childhood, the person becomes constantly hungry which often leads to obesity and type 2 diabetes. There is also typically mild to moderate intellectual impairment and behavioral problems. Prader-Willi syndrome has no cure.

About INSYS Therapeutics, Inc.

Founded in 1998 and headquartered in Chandler, Arizona, INSYS is a commercial-stage specialty pharmaceutical Company that develops and commercializes innovative supportive care products to address chemotherapy-induced nausea and vomiting (CINV), pain management, and other central nervous system disorders.

Stock Performance Snapshot

April 30, 2018 - At Monday's closing bell, INSYS Therapeutics' stock declined 3.97%, ending the trading session at $7.01.

Volume traded for the day: 510.38 thousand shares.

Stock performance in the last month – up 16.06%

After yesterday's close, INSYS Therapeutics' market cap was at $496.87 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors